On March 28, 2013, Wilson, Timothy R.; Koeppen, Hartmut; Merchant, Mark; Settleman, Jeffrey published a patent.SDS of cas: 924909-16-0 The title of the patent was Combinations comprising c-Met antagonists and B-raf antagonists for treatment of cancer. And the patent contained the following:
The invention provides combination therapies for treating a pathol. condition, such as cancer, wherein a c-met antagonist (e.g. crizotinib, tivantinib, anti-HGF antibody, onartuzumab) is combined with a B-raf antagonist (e.g. vemurafenib), thereby providing significant antitumor activity. C-met expression was inversely correlated with sensitivity to vemurafenib treatment. In one aspect, provided are methods for treating a cancer patient who has increased likelihood of developing resistance to B-raf antagonist comprising administering an effective amount (in combination) of B-raf antagonist and c-met antagonist. In addition, patients with B-raf mutant melanoma who had higher levels of circulating hepatocyte growth factor (HGF) showed substantially reduced progression free survival and overall survival when treated with B-raf antagonist, relative to patients with lower circulating HGF levels treated with B-raf antagonist. The experimental process involved the reaction of 1-(4-Methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-4-ol(cas: 924909-16-0).SDS of cas: 924909-16-0
The Article related to combination chemotherapy cmet antagonist braf inhibitor cancer treatment, gdc0712 preparation antitumor combination chemotherapy cmet braf drug target, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.SDS of cas: 924909-16-0
Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics